4.40

0.23% 0.01

After Hours: 4.38 -0.02 -0.45%

Arbutus Biopharma Corp (ABUS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Arbutus Biopharma Corp stock is traded at $4.40, with a volume of 497.75K. It is up +0.23% in the last 24 hours and down -1.79% over the past month. Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Previous Close:

$4.39

Open:

$4.44

24h Volume:

497.75K

Relative Volume:

0.22

Market Cap:

$866.53M

Revenue:

$14.08M

Net Income/Loss:

$-33.50M

P/E Ratio:

-25.09

EPS:

-0.1754

Net Cash Flow:

$-39.72M

1W Performance:

+6.02%

1M Performance:

-1.79%

6M Performance:

-4.56%

1Y Performance:

+25.36%

1-Day Range:

$4.35

$4.54

1-Week Range:

$4.01

$4.54

52-Week Range:

$2.94

$5.10

Arbutus Biopharma Corp Stock (ABUS) Company Profile

Name

Arbutus Biopharma Corp

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

604-419-3200

Address

701 VETERANS CIRCLE, WARMINSTER, PA

Employee

Twitter

@arbutusbio

Next Earnings Date

2026-05-13

Latest SEC Filings

ABUS's Discussions on Twitter

Compare ABUS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABUS Arbutus Biopharma Corp	4.40	864.57M	14.08M	-33.50M	-39.72M	-0.1754
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-02-22	Upgrade	Jefferies	Hold → Buy
Feb-25-21	Initiated	Jefferies	Hold
Dec-17-20	Initiated	H.C. Wainwright	Buy
Jul-27-20	Resumed	JMP Securities	Mkt Outperform
Jul-24-20	Downgrade	Robert W. Baird	Outperform → Neutral
May-19-20	Upgrade	Wedbush	Neutral → Outperform
Mar-06-20	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-20-20	Initiated	Robert W. Baird	Outperform
Feb-05-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Oct-07-19	Reiterated	B. Riley FBR	Buy
Oct-04-19	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-16-18	Upgrade	B. Riley FBR	Neutral → Buy
Oct-15-18	Upgrade	Wedbush	Underperform → Neutral
Oct-12-18	Reiterated	Chardan Capital Markets	Buy
Jul-06-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Mar-19-18	Resumed	Chardan Capital Markets	Buy
Mar-19-18	Downgrade	Wedbush	Outperform → Neutral
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy
Apr-04-17	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-01-17	Reiterated	Wedbush	Outperform
Dec-13-16	Downgrade	Chardan Capital Markets	Buy → Neutral
Nov-30-16	Upgrade	Chardan Capital Markets	Neutral → Buy

View All

Arbutus Biopharma Corp Stock (ABUS) Latest News

May 01, 2026

Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey

May 01, 2026

Apr 30, 2026

5 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey

Apr 30, 2026

Apr 28, 2026

Whitefort lifts Arbutus (ABUS) economic stake to 9.8% - Stock Titan

Apr 28, 2026

Apr 24, 2026

Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat

Apr 24, 2026

Apr 23, 2026

FDA grants Arbutus Biopharma drug fast track designation - Pennsylvania Business Report -

Apr 21, 2026

Apr 18, 2026

Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN

Apr 18, 2026

Apr 17, 2026

Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability - Insider Monkey

Apr 17, 2026

QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm

Apr 17, 2026

Apr 16, 2026

Whitefort Capital Management, LP Increases Stake in Arbutus Biop - GuruFocus

Apr 16, 2026

Apr 15, 2026

Arbutus Biopharma (ABUS) Receives FDA Fast Track Designation for Imdusiran - GuruFocus

Apr 15, 2026